IL-17AF Inhibitors & Biosimilars
1 drugsAbout IL-17AF
Interleukin-17AF (IL-17AF) is a pro-inflammatory cytokine heterodimer composed of IL-17A and IL-17F subunits, crucial for immune responses. As a key mediator in inflammatory pathways, it has emerged as a significant drug target in immunology.
IL-17AF is a compelling therapeutic target due to its involvement in driving inflammation. Currently, there is no genetic evidence data available linking IL-17AF to specific diseases.
IL-17AF is targeted by one FDA-approved biologic drug, BIMZELX (UCB INC), which has 5 indications in immunology. This first approval occurred in 2023.
Top IL-17AF Drugs
The competitive landscape is concentrated, with UCB INC holding the only approved drug.
High market concentration suggests high entry barriers or first-mover advantage for UCB INC.
IL-17AF Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets IL-17AF, using biologic (other) modality.
Small molecule or alternative modalities represent a whitespace opportunity for differentiation.
IL-17AF Clinical Trials 53 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on IL-17AF. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 7 | 4 | 1 | 2 | 80% |
| Phase 2 | 16 | 12 | 0 | 4 | 100% |
| Phase 3 | 25 | 19 | 0 | 6 | 100% |
| Phase 4 | 5 | 2 | 1 | 2 | 67% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
IL-17AF Drug Approval Timeline (2023 - 2023)
The first and only drug approval for IL-17AF was BIMZELX in 2023.
Recent entry suggests potential for rapid growth or risk of market saturation.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 13 (4 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on IL-17AF. A trial counts if an approved drug acting on IL-17AF is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.